The lymphocyte to monocyte ratio improves the IPI‐risk definition of diffuse large B‐cell lymphoma when rituximab is added to chemotherapyAlessandro Rambaldi, Corrado Tarella, Alberto De Crescenzo et al.|American Journal of Hematology|2013Cited by 65
A Recent Update of Three Consecutive Prospective Trials with High-Dose Therapy and Autograft, without or with Rituximab, as Primary Treatment for Advanced-Stage Follicular Lymphoma (FL) Shows a Sizeable Group of Patients Surviving in Continuous Complete Remission up to 16 Years After the End of Treatment: Should We Still Consider FL An Incurable Disease ?.Corrado Tarella, Paolo Corradini, Umberto Vitolo et al.|Blood|2009Cited by 4
The Peripheral Blood Lymphocyte to Monocyte Ratio At Diagnosis Is a Potent Outcome Predictor in Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Long-Term Analysis On 973 Patients Receiving Chemotherapy with or without RituximabAlessandro Rambaldi, Corrado Tarella, Angela Gueli et al.|Blood|2012Cited by 3